Xenon Pharmaceuticals Inc. 8-K

What Happened

• Xenon Pharmaceuticals Inc. (XENE) announced details for its 2026 annual meeting of shareholders in a SEDAR+ filing submitted March 13, 2026 and reported that announcement on an SEC Form 8-K (Item 8.01).
• The Form 8-K also notes that the related SEDAR+ filing (Exhibit 99.1) and the Inline XBRL cover page (Exhibit 104) were furnished to the SEC on March 13, 2026. The report was signed by Thomas P. Kelly, Chief Financial Officer.

Key Details

• Filing date with the SEC: March 13, 2026.
• Item reported: 8.01 (Other Events) — announcement of the 2026 annual meeting and record date via SEDAR+.
• Exhibits furnished: 99.1 (SEDAR+ filing submitted March 13, 2026) and 104 (Cover Page Interactive Data File).
• Exhibit material is “furnished” to the SEC (deemed furnished, not filed) per Item 9.01.

Why It Matters

• Shareholders should watch the SEDAR+ filing for the specific meeting date, record date and voting information needed to participate in the 2026 annual meeting.
• This filing does not include financial results or management changes; it is an administrative disclosure about shareholder meeting logistics.